Our-Mission
slide00

World lupus day 2016

World lupus day (WLD), reflects the necessity for heightened public knowledge, ameliorated patients’ healthcare services and to increase investigations on the etiology and a cure for systemic lupus erythematosus (SLE), enhanced physicians’ diagnosis and finally treatment of this disease.

Read the story

World Diabetes Day

World Diabetes Day takes place on November 14 of each year
World Diabetes Day (WDD), on the 14th November every year, now becomes a globally-celebrated event to increase awareness about diabetes and specially to improve and treat diabetic kidney disease

World Diabetes Day 2015
Healthy eating and diabetes

In 2015, WDD activities and materials focus on healthy eating as a key factor in the fight against diabetic kidney disease and a cornerstone of health and sustainable development….
read the story…..


Implication for health policy/practice/research/medical education
World diabetes day was envisaged in 1991 by World Health Organization (WHO) and the International Diabetes Federation in response to increasing concerns about the escalating health threat that diabetes currency poses. The theme of this year (2015) is act today to   change tomorrow concentrating on the importance of starting the day with a healthy breakfast to help prevent the onset of type II diabetes and effectively manage all types of diabetes to avoid complications.

World Kidney Day 2016

The next World Kidney Day will be held on Thursday March 10, 2016. The theme for 2016 will focus on Kidney Disease & Children: Act Early to Prevent It. To get the 2016 campaign started or for more information on World Kidney Day,

World Kidney Day 2016: Awareness for Saving Kidneys
The general message of the world kidney day is a concerted knowledge against the illnesses that lead to end-stage kidney failure, through better education, improved economic opportunity, increasing community outreach and access to protective medicine for individuals at the highest risk. These might end the unacceptable relationship between chronic renal failure and disadvantages in these societies. Annually, world kidney day reminds us that renal disease is a common harmful complication and in many cases treatable. The task of the world kidney day is to develop consciousness so that everybody cares for their kidneys and, if suitable, check and assess if they are at risk of renal disease. Prevention of renal disease, prompt recognition, and following renal protection protocols are serious goals for the world kidney day. As an annual global alertness and education event, the 2013 World Kidney Day focused on increased awareness of acute renal failure among hospital staff and physicians and the necessity for a public awareness campaign to clarify this hazardous situation and make ‘kidney attack’ recognizable for the community, similar to that conducted by stroke and heart attack campaigns. Currently, acute renal failure is inefficiently directed in clinical education and training, and mainly ignored by people. Prevention of renal disease, prompt recognition, and following renal protection are serious goals of the world kidney day.

read the story

Our Mission

To prevent and treat diabetic kidney disease and to improve the lives of all individuals affected by diabetes.

World kidney day 2015

Mohammad Reza Tamadon, Mehrdad Zahmatkesh


World Kidney Day on March 12, 2015: Kidney Health for All


World Kidney Day will be celebrated on March 12, 2015. This time the theme is on Kidney Health for All.

Implication for health policy/practice/research/ medical education
Diagnosis and treatment of renal diseases in a timely manner are important. Assessing cardiovascular status (and risk factors such as smoking and lipid profile) is essential, because it has an important role in mortality. Also, due to the possibility of osteoporosis and its subsequent fractures, bone densitometry is important. If the glomerular filtration rate is less than 30 mL/min, and lower the patient should be referred to a nephrologist. The slogan of the world in 2015 on March 12, 2015, is to invite everyone to drink a glass of water and give one too to celebrate their kidneys. This is a symbolic gesture to remember that kidneys are vital organs and that they should be cared; it is a way to make people more conscious about their lifestyle choices.

Tamadon MR, Zahmatkesh M.  World kidney day 2015. J Parathyr Dis 2015;3(2):34-36

The theme of World Hypertension Day 2014: Know your Blood Pressure

Firstly World Hypertension Day inaugurated in May 2005 and has become an annual event ever since. The aim of the World Hypertension Day is to promote public alertness of high blood pressure and to promote citizens of all countries to prevent and control this silent killer, the modern epidemic.World Hypertension Day was initiated firstly by the World Hypertension League.High blood pressure (hypertension) is considered as the silent killer since it has no apparent symptoms. Investigations show that the disease involves more than 1.5 billion people global, and around seven million people die every year from hypertension.

Nasri H. Know your blood pressure; the theme of world hypertension day 2014.Iran J Public Health. 2014 Aug; 43(8):1154-6.

History of World Kidney Day

World Kidney Day started in 2006 and has not stopped growing ever since. Every year, the campaign highlights a particular theme.
•    2015 Kidney Health for All
•    2014 Chronic Kidney Disease (CKD) and aging
•    2013 Kidneys for Life – Stop Kidney Attack!
•    2012 Donate – Kidneys for Life – Receive
•    2011 Protect your kidneys: Save your heart
•    2010 Protect your kidneys: Control diabetes
•    2009 Protect your kidneys: Keep your pressure down
•    2008 Your amazing kidneys!
•    2007 CKD: Common, harmful and treatable
•    2006 Are your kidneys OK?

Diabetic kidney disease: a report from an ADA Consensus Conference

Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME. Diabetes Care. 2014; 37(10):2864-83.

Nasri H, Ardalan MR, Rafieian-Kopaei M. Mechanistic Impacts of Medicinal Plants in Diabetic Kidney Disease. Iran J Public Health. 2014 Sep; 43(9):1311-3.
Herbal medicines have been traditionally used for the treatment of diabetes mellitus. Some medicinal plants contain compounds that can be effective in impaired glucose tolerance. Recent pre-clinical and clinical trials have also demonstrated their beneficial effects on diabetes associated complications, especially on diabetic nephropathy. Although some plants have been shown to have toxic effects, hut several species with beneficial effects on diabetes mellitus and in the prevention of kidney complications in diabetic patients have been identified. These effects have been observed with both bioactive compounds and crude extracts isolated from anti-diabetic plants. In particular, plants such as Sclerocarya birrea, Persea americana, Ficus thonningii and Helichrysium ceres have been shown to have renoprotective effects. Isolated compounds such as oleanolic acid have also been shown to possess renoprotective effects in experimental diabetes in animals. Hence oleanolic acid caused an increase in renal Na+ excretion in streptozotocin-induced diabetic rats, which was mediated by an improvement in glomerular filtration rate , read the story

Stages of Chronic Kidney Disease

Stage    Description    GFR (mL/min)
1    Kidney damage with normal or raised GFR    ≥90
2    Kidney damage with mild decrease in GFR    60-89
3    Moderate decrease in GFR    30-59
4    Severe decrease in GFR    15-29
5    Kidney Failure   

Open Access

All original research papers published by Society of Diabetic Nephropathy Prevention are made freely and permanently accessible online immediately upon publication. Open access publishing allows an immediate, world-wide, barrier-free, open access to the full text of research papers, which is in the best interests of the scientific community.
High visibility for maximum global exposure with open access publishing model
Rigorous peer review of research papers
Prompt faster publication.
Society of Diabetic Nephropathy Prevention, comply the Open Access Scholarly Publishers Association (OASPA), adheres to its CODE OF CONDUCT, and follows its criteria and supports OASPA's Statement on open Access.

About us

 

Founder of Society of Diabetic Nephropathy Prevention

 

Professor Hamid Nasri, Section of Nephropathology, Division of Nephrology Department of  Internal Medicine, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.

 

 

 

 

 

 

 International affairs

 

Seyyed Amir Yasin Ahmadi
Lorestan University of Medical Sciences, Khorramabad, Iran

 

 

 

 

 

 

Address: No 8, 23 Lane, Farabi North Street, Freiburg Avenue. Isfahan, Iran.

Postal Code: 81687-95341

Post Box: 81655-963

Tel: +98 311 669 2609

Cell phone: +98 913 382 0680 

Email: hamidnasri[at]med.mui.ac.ir ,  hamidnasri[at]yahoo.com

 

 


Society of Diabetic Nephropathy Prevention (SDNP) is a non-profitable and a non-governmental organization (NGO) dedicated, to prevent and treat diabetic kidney disease and to improve the lives of all individuals affected by diabetes. The aim of SDNP is to encourage researches in the field of renal pathology/nephrology, especially in the field of renal protection by searching for novel ways in medicine, particularly for kidney injury prevention and treatment. The SDNP has also a publishing center which publishes two journals such as “Journal of Nephropathology" and Journal of Nephropharmacology, mostly in their field of research aims.

Society of Diabetic Nephropathy Prevention, is an Open Access publisher, founded in 2012. When publishing in any of Society of Diabetic Nephropathy Prevention’s journals, authors retain the copyright of their article, which is freely distributed under the Creative Commons Attribution License, permitting the unrestricted use, distribution, and reproduction of the article in any medium, provided the original work is properly cited.

Society of Diabetic Nephropathy Prevention serves the worldwide academic communities and contributes to the progress and application of science, by delivering superior scientific publications and scientific information solution provider that enable advancement in scientific research. More than 25 professional editorial board members and international reviewers support our publishing activities.

Journal of Nephropathology

  

 

Journal of  Nephropharmacology

Editorial Policies Adopted by Scholarly Journals Published by Society of Diabetic Nephropathy Prevention (new 2015)

Editorial Policies Adopted by Scholarly Journal Published by Society of Diabetic Nephropathy Prevention
Authorship
The ICMJE recommends that authorship be based on the following 4 criteria:
1. Substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data.
2. Drafting the work or revising it critically for important intellectual content.
3. Final approval of the version published.
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Read more: Editorial Policies Adopted by Scholarly Journals Published by Society of Diabetic Nephropathy...

Publication Ethics

Society of Diabetic Nephropathy Prevention is committed to maintaining high standards through a rigorous peer-review together with strict ethical policies. Any infringements of professional ethical codes, such as plagiarism, fraudulent use of data, bogus claims of authorship, should be taken very seriously by the editors with zero tolerance.
Ethical standards for publication exist to ensure high-quality scientific publications, public trust in scientific findings, and that people receive credit for their ideas. Society of Diabetic Nephropathy Prevention comply the rules of Committee on Publication Ethics (COPE) and abides by its Code of Conduct and aims to adhere to its Best Practice Guidelines.
Society of Diabetic Nephropathy Prevention follows the Code of Conduct of the Committee on Publication Ethics (COPE), and follows the COPE Flowcharts for Resolving Cases of Suspected Misconduct.
The submitted manuscript should not have been previously published in any form and must not be currently under consideration for publication elsewhere.
Citation Manipulation
Submitted manuscripts that are found to include citations whose primary purpose is to increase the number of citations to a given author’s work, or to articles published in a particular journal, will incur citation manipulation sanctions.

Duplicate Submission
Manuscripts that are found to have been published elsewhere, or to be under review elsewhere, will incur duplicate submission/publication sanctions. If authors have used their own previously published work, or work that is currently under review, as the basis for a submitted manuscript, they are required to cite the previous work and indicate how their submitted manuscript offers novel contributions beyond those of the previous work.
Data Fabrication and Falsification

Submitted manuscripts that are found to have either fabricated or falsified experimental results, including the manipulation of images, will incur data fabrication and falsification sanctions.
Improper Author Contribution or Attribution
All listed authors must have made a significant scientific contribution to the research in the manuscript and approved all its claims. It is important to list everyone who made a significant scientific contribution, including students and laboratory technicians.
Redundant Publications
Redundant publications involve the inappropriate division of study outcomes into several articles.
Plagiarism
All journals published by Society of Diabetic Nephropathy Prevention are committed to publishing only original material, i.e., material that has neither been published elsewhere, nor is under review elsewhere. Manuscripts that are found to have been plagiarized from a manuscript by other authors, whether published or unpublished, will incur plagiarism sanctions.

Sanctions
In the event that there are documented violations of any of the above mentioned policies in any journal, regardless of whether or not the violations occurred in a journal published by Society of Diabetic Nephropathy Prevention, the following sanctions will be applied:
  Immediate rejection of the infringing manuscript
Immediate rejection of every other manuscript submitted to any journal published by Society of Diabetic Nephropathy Prevention by any of the authors of the infringing manuscript.
Prohibition against all of the authors for any new submissions to any journal published by Society of Diabetic Nephropathy Prevention, either individually or in combination with other authors of the infringing manuscript, as well as in combination with any other authors. This prohibition will be imposed for a minimum of 36 months.
Prohibition against all of the authors from serving on the Editorial Board of any journal published by Society of Diabetic Nephropathy Prevention.
In cases where the violations of the above policies are found to be particularly egregious, the publisher reserves the right to impose additional sanctions beyond those described above.

Human & Animal Rights

DETAILES of RULES AND GUIDELINES FOR RESPONSIBLE CONDUCT OF RESEARCH WITH EXPERIMENTAL ANIMALS

A) GENERAL PROVISIONS

Article 1
RULES AND GUIDELINES FOR RESPONSIBLE CONDUCT OF RESEARCH WITH EXPERIMENTAL ANIMALS of the Society of Diabetic Nephropathy Prevention defines protected animal species, experimental procedures (ethical and unethical), principles of ethical experimental work with animals, training of the researchers for such work, Ethical Committee for Work with Experimental Animals of the Society of Diabetic Nephropathy Prevention in  Isfahan, Iran (its tasks, work principles, composition and way of forming, Ethical Committee further in the text), procedure of getting the license to work with experimental animals by the Ethical Committee, as well as the procedures in case of neglect of the rules set by the Ethical Committee and decisions adopted based on the Rules.
B) PROTECTED ANIMAL SPECIES AND EXPERIMENTAL PROCEDURES

Article 2
Protected species are vertebrates (experimental animals further in the text), except for the humans, including all developmental stages from the middle of gestation.

Article 3
Ethical experimental procedures are those that involve the procedures of manipulation of experimental animals aiming to obtain new knowledge in the biomedicine field and thus to contribute to general development of medicine and which could cause suffering, pain and permanent disability of experimental animals (disease, injury, stress etc.).

Article 4
Ethical experimental procedures involve also the purposeful sacrificing of experimental animals in order to get isolated organs or sacrificing at the end of experiment.
Sacrificing methods must not cause suffering and pain. Death has to be instantaneous (the procedures which satisfy these criteria are the administration of triple dose of an intravenous anesthetic, inhalation of appropriate mixture of gases in special chambers, cervical dislocation, decapitation etc.).

Article 5
Non-ethical experimental procedures are those manipulations with experimental animals which could cause pain, suffering, permanent damage or death, and are not aimed at creating new knowledge in biomedical sciences and do not contribute to the development of medicine. Among these procedures we may include demonstrations of already known facts on experimental animals, except when the involvement of animals is unavoidable for the achievement of educative goals. Instead of this, computer simulations or other didactic devices are recommended. The use of animals in practical teaching, in exceptional cases when educational goals cannot be achieved otherwise, is possible at the Society of Diabetic Nephropathy Prevention after the request of the performing teacher and the aprovement of the department in question, only with special permission of the Ethical Committee (issued for specific time) and with respect to the stipulations of the Rules.

Article 6
The Rules does not consider the procedures of marking of experimental animals which can cause momentary pain, investigation of new veterinary agents and other veterinary diagnostic and treatment procedures.

Article 7
In planning experimental work with animals it is necessary to respect the following ethical principles. Principle of replacement: whenever possible instead of experimenting on a protected species, we should use alternative experimental models in vitro (eg. cell cultures, isolated organs, microorganisms) and computer simulations; Principle of reduction: using the smallest possible number of experimental animals, according to the statistical requirements; Principle of quality: use of healthy animals, appropriate species and age, properly kept and if possible in kinship. It is mandatory to use appropriate statistical methods in the evaluation of results. Only appropriately trained investigators should be included in experimental work with animals. Experimental protocols have to predict scientifically valid answer to the research goals.

C) RESEARCHERS

Article 8
Researchers should be appropriately trained to work with experimental animals. The required qualification degree depends on the experimental protocol itself. Researchers have to submit the confirmation that they are trained to work with experimental animals. This could be a certificate of the course attended at the Society of Diabetic Nephropathy Prevention or any related scientific/research institution in the country or abroad, with similar or stricter regulations from those contained in the rules.
Experimental Subjects
All studies involving human subjects or human tissue must be in accordance with the principles set out in the Declaration of Helsinki and must have been formally approved by the appropriate institutional review board, ethical review committee, or equivalent. All manuscripts should indicate that such approval was obtained. The study populations should be described in detail. In many studies details of age, race, and sex are important. In experiments involving any significant risk or discomfort to subjects, it should be documented that informed consent was obtained from the subjects and that an institutional human research committee had approved the investigations. In text, tables and figures of subjects must be identified by number or letter rather than by initials or names. Photographs of patients' faces should be included only if scientifically relevant. Authors should obtain written consent from the patient for use of such photographs.


ETHICAL GUIDELINES FOR PUBLICATION OF RESEARCH IN Journals of Society of Diabetic Nephropathy Prevention
 The Editorial Board is keenly aware of the importance of formulating and disseminating rules of good conduct for authors, reviewers, and editors. Equally important is the establishment of due process for alleged or apparent improprieties. The Ethical Committee of the Society of Diabetic Nephropathy Prevention has approved the following Ethical Guidelines for our Editorial Board, reviewers, and authors submitting manuscripts. The following statement is not meant to be all-inclusive but is provided in sufficient detail to give a clear understanding of ethical considerations to all concerned.

Introduction
The fundamentals of good conduct as they apply to research are honesty, fairness, good manners, and the subordination of self-interest to the common interest of our profession and our society. In these notes, the Editorial Board sets forth its rules of good conduct for authors, reviewers, and editors.

Obligations of Authors

Authorship Conditions
An author should have participated in either the conception or planning of the work, the interpretation of the results and the writing of the paper. An acknowledgment accompanying the paper is appropriate recognition for others who have contributed to a lesser extent, e.g., provision of clones, antisera or cell lines, or reading and reviewing manuscripts in draft. The signature of each author on the Affirmation of Originality and Copyright Release form that must be submitted with the manuscript indicates that all authors have had a part in the writing and final editing of the report, all have been given a copy of the manuscript, all have approved the final version of the manuscript, and all are prepared to take public responsibility for the work, sharing responsibility and accountability for the results.

Authorship Obligations
The foremost obligation of an author is to present a clear, honest, accurate, and complete account of the research performed. Each manuscript should describe a complete study or a completed phase of an extended study. Fragmentation of reports should be avoided. When some of the results are to appear in another journal, in publications of congresses, symposia, workshops, etc., details plus a copy of the other paper(s) should be supplied to the editor. Any preliminary accounts or abstracts of the work, already published, must be referenced in the complete report.
The author has an obligation to: 1) describe the work in sufficient detail to allow others to repeat the work; 2) adhere to the journals' policy regarding preparation of digital images as outlined below; 3) include all relevant data, including those which may not support the hypothesis being tested; 4) cite those publications which have a direct bearing on the novelty and interpretation of the results; 5) make unique resources available to other investigators for academic research purposes, as a condition of publication. The Society of Diabetic Nephropathy Prevention endorses the philosophy of open exchange of research materials and requires this; 6) ensure no substitution, addition, or deletion of data or text during the proof correction process (after acceptance). Answers to author queries and changes to typographical or printer's errors may be made to proofs. Any other changes will require that the proofs be returned to the editorial office for re-review of the manuscript; 7) If there are any additions, deletions, or changes in position of the names that appear in the authorship line of the originally submitted manuscript, the corresponding author must send to the Editorial Board a brief letter, signed by all authors, stating that they agree to the change.

Image Integrity
When preparing digital images, authors must adhere to the following guidelines (as stated in Reference 8):
•    No specific feature within an image may be enhanced, obscured, moved, removed, or introduced.
•    Adjustments of brightness, contrast, or color balance are acceptable if they are applied to the entire image and as long as they do not obscure, eliminate, or misrepresent any information present in the original.
•    The grouping of images from different parts of the same gel, or from different gels, fields, or exposures must be made explicit by the arrangement of the figure (e.g., dividing lines) and in the figure legend.
Deviations from these guidelines will be considered as potential ethical violations.
Note that this is an evolving issue, but these basic principles apply regardless of changes in the technical environment. Authors should be aware that they must provide original images when requested to do so by Editors-in-Chief who may wish to clarify an uncertainty or concern.

Peer Review Process

Peer Review Process in Journals of Society of Diabetic Nephropathy Prevention (SDNP)


Journals of SDNP accept manuscripts report novel findings, which could result in impacts on biomedical sciences. Quality and topic of submitted manuscript beside the priority of research field are the least considered criteria in each manuscript before entering in formal review process. Any type of submissions containing scientific information necessitates review process to ensure content quality.
 Technical editor checks the format and style of manuscript prior to review process to assure its compatibility with Journals’ guidelines for authors. Checking compatibility continues in whole of the review process and publication. In cases when the authors have not considered the guidelines, the manuscript will be sent back to the authors for compatibility. Each submitted manuscript will be considered by the editor-in-chief or one of associate editors in the editorial board. If it meets the minimum criteria to be included in review process, one of the editors (topic expert) selects at least two external reviewers for detailed evaluation process. Selection of reviewers is based on their scientific background and experience, previous works, authors’ suggestion, and expertise. Reviewers promise to undertake the confidentiality of materials previous to ePublication. In the review process of Journals of SDNP, reviewers stay anonymous, but authors’ names are declared to reviewers. Also, authors could suggest reviewers for their manuscript.
Editor receives the reviewers’ comments and sends them along with decision letter to corresponding author. Final decision on each manuscript will be made by the assigned editor of the manuscript. While Journals of SDNP are, a rapid response journal, so this process takes not more than three weeks. Decision letter determines the status of manuscript in five ways:
1. Acceptance: the manuscript could be ePublished. This process lasts two weeks.
 Before ePublication, corresponding author could verify a proof copy of the paper. After ePublication, paper will be in a queue to be published in one of the issue of journals, related to SDNP
2. Minor revises: authors will receive comments upon their manuscript, at which point the authors will be asked to submit a revised copy beside cover letter showing authors’ rejoinders, and also a marked copy utilizing Track Changes in Review menu of Microsoft Word Documents. Revised manuscript should be submitted in one month after decision letter. Unless, authors need to go through a resubmission process.
3. Major revises: it means a chance to reorganize the manuscript to meet the required scientific criteria for another review process. Authors should pay more attention to reviewers’ comments and focus on their highlighted points. Editor may/may not request the authors to resubmit their revised manuscript beside cover letter and a marked copy. Revised manuscript should be submitted in one month after decision letter. Otherwise, authors need to go through a resubmission process.
4. Reject: in most cases, methodological and scientific concerns are the main origins of rejection. Causes of rejection will be sent to the authors to provide more chance for them for publication in other journals.
5. Withdraw: if the manuscript does not meet the scopes of our journals, it will be withdrawn with suggestion to be sent to another journal.
SDNP may invite prominent experts to submit editorials or review papers in special topics, which will be reviewed by editors only. Also commentaries may pass the same way in review process.
In cases that concerns arise during review process about statistical test, methodology or techniques applied in research, editor may request independent internal/external experts to comment before final decisions.
As the final point, we strongly suggest authors to observe research and publication ethics in their manuscript, as reporting of any unethical issue during steps of review may lead to the rejection of the work by Journals of SDNP. Also, the authors should consider that they are in the charge of all materials (scientific and ethical) that they provide in their articles.
All of editors and reviewers of SDNP do their utmost to keep the quality of disseminated scientific works to ensure the solid impact of papers on biomedical fields. In SDNP, the review process lasts maximum one month.

Conflicts of Interest

Articles should be published with statements or supporting documents, such as the ICMJE conflict of interest form, declaring:
•    Authors’ conflicts of interest; and
•    Sources of support for the work, including sponsor names along with explanations of the role of those sources if any in study design; collection, analysis, and interpretation of data; writing of the report; the decision to submit the report for publication; or a statement declaring that the supporting source had no such involvement; and
•    Whether the authors had access to the study data, with an explanation of the nature and extent of access, including whether access is on-going.
To support the above statements, editors may request that authors of a study sponsored by a funder with a proprietary or financial interest in the outcome sign a statement, such as “I had full access to all of the data in this study and I take complete responsibility for the integrity of the data and the accuracy of the data analysis.”

Editorial Policy of Publisher

 Editorial Policies Adopted by Scholarly Journals Published by Society of Diabetic Nephropathy Prevention

Authorship

The ICMJE recommends that authorship be based on the following 4 criteria:

1. Substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data.

2. Drafting the work or revising it critically for important intellectual content.

3. Final approval of the version published.

4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

In addition to being accountable for the parts of the work he or she has done, an author should be able to identify which co-authors are responsible for specific other parts of the work. In addition, authors should have confidence in the integrity of the contributions of their coauthors. All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be listed in an Acknowledgements section. Participation solely in the acquisition of funding, the gathering of data, technical help, writing assistance, and general supervision of the research group does not warrant authorship. Financial and material support should also be acknowledged. Please guarantee that anyone stated in the Acknowledgements section has granted its clearance for permission to be listed.

Contributorship statement

A contributorship statement is required for every manuscript submitted and should state who has contributed what to the planning, conduct, and reporting of the work described in the article.

Acknowledgements

Recognize individuals who provided assistance to the project. Report all sources of grant and other support for the project or study, including funds received from contributors, institutions and commercial sources. Consultancies and funds paid directly to investigators must also be listed.

Authorship changes

Any change in authorship (i.e., order, addition, and deletion of authors) after initial submission must be approved by all authors. Authors should determine the order of authorship among themselves. In addition, any alterations must be clarified to the Editor/Editor-in-chief.

Competing interests

A competing interest exists when professional judgment concerning a primary interest (such as patients’ welfare or the validity of research) may be influenced by a secondary interest (such as financial gain - employment, consultancies, stock ownership or options, honoraria, patents, and paid expert- testimony or personal relationship). There is nothing unethical about a competing interest but it should be acknowledged and clearly stated. All authors must declare all competing interests in their covering letter and in “Competing Interests” section at the end of the manuscript file (before the references). Authors with no competing interests to declare should obviously state that.

The policy of Society of Diabetic Nephropathy Prevention is that none of the editors should have any financial relationship with any biomedical company.

Ethical approval of research/Publication Ethics

Society of Diabetic Nephropathy Prevention journals are following of the Committee on Publication Ethics (COPE) and aim to adhere to its Best Practice Guidelines.

We strongly consider allegations of publication misconduct, both before and after publication, and we reserve the right to contact authors' institutions, funders, or regulatory bodies if needed. If we find conclusive evidence of misconduct, we will take steps to correct the scientific record, which may include supplying a correction or retraction.

Authors are expected to be aware of publication ethics, specifically with regard to authorship, dual submission, plagiarism, figure manipulation, competing interests, and compliance with standards of research ethics. In cases of suspected misconduct, we will follow COPE standards and practices and may seek advice from the COPE forum if needed.

Statement of ethics approval

We require every research article submitted to include a statement that the study obtained ethics approval (or a statement that it was not required and why), including the name of the ethics committee(s) or institutional review board(s), the number/ID of the approval(s), and a statement that participants gave informed consent before taking part. Even when a study has been approved by a research ethics committee or institutional review board, editors may ask authors for more detailed information about the ethics of the work.

Patient consent and confidentiality

Any article that contains personal medical information about an identifiable living individual requires the patient’s explicit consent before we can publish it. We would like the patient to sign our consent form, which requires the patient to have read the article.

If consent cannot be obtained because the patient cannot be traced then publication will be possible only if the information can be sufficiently anonymized. Anonymisation means that neither the patient nor anyone else could identify the patient with certainty.

If the patient is dead the authors should seek permission from a relative (as a matter of courtesy and medical ethics). If the relatives are not contactable we will balance the worthwhileness of the case, the likelihood of identification, and the likelihood of offence if identified in making a decision on whether we should publish without a relative’s consent.

Our policy on obtaining consent for publication of pictures of patients is a subset of our general policy on patient confidentiality. If there is any chance that a patient may be identified from a photograph or other image or from its legend or accompanying text we need the patient’s written consent to publication by Society of Diabetic Nephropathy Prevention.

Images – such as X- rays, laparoscopic images, ultrasound images, pathology slides, or images of undistinctive parts of the body – may be used without consent so long as they are anonymized by the removal of any identifying marks and are not accompanied by text that could reveal the patient’s identity through clinical or personal detail.

Research reporting guidelines

Authors are encouraged to use the relevant research reporting guidelines for the study type provided by the EQUATOR Network. This will ensure that you provide enough information for editors, peer reviewers and readers to understand how the research was performed and to judge whether the findings are likely to be reliable.

The key reporting guidelines are:

Randomized controlled trials (RCTs):CONSORT guidelines

Systematic reviews and meta-analysis: PRISMA guidelines and MOOSE guidelines

Observational studies in epidemiology: STROBE guidelines and MOOSE guidelines

Diagnostic accuracy studies: STARD  guidelines

Quality improvement studies: SQUIRE guidelines

Clinical trial registration

Based on ICMJE recommendations, a clinical trial defines as “any research project that prospectively assigns people or a group of people to an intervention, with or without concurrent comparison or control groups, to study the cause-and-effect relationship between a health-related intervention and a health outcome”.

In agreement with the ICMJE , journals published by Society of Diabetic Nephropathy Prevention will not consider reports of clinical trials unless they were registered prospectively before recruitment of any participants.

Trial registration

As a condition of consideration for publication, journals published by Society of Diabetic Nephropathy Prevention require registration of all trials in a public trials registry that is acceptable to the ICMJE (any registry that is a primary register of the WHO International Clinical Trials Registry Platform www.who.int/ictrp /network/primary/en/index.html or in ClinicalTrials.gov, which is a data provider to the WHO ICTRP).

Plagiarism detection

Journals published by Society of Diabetic Nephropathy Prevention use iThenticate software, which is a plagiarism detector service that verifies the originality of content submitted before publication. If plagiarism is identified, we will follow COPE guidelines.

Plagiarism includes, but is not limited to:

Directly copying text from other sources

Copying ideas, images, or data from other sources

Reusing text from your own previous publications

Using an idea from another source with slightly modified language

If plagiarism is detected during the peer review process, the manuscript may be rejected. If plagiarism is detected after publication, we reserve the right to issue a correction or retract the paper, as appropriate. We reserve the right to inform authors' institutions about plagiarism detected either before or after publication.

Peer review policy

Journals from Society of Diabetic Nephropathy Prevention review all manuscript submissions, internally or externally.

Original research articles authored by a member of a journal’s editorial team are independently peer reviewed; an editor will have no input or influence on the peer review process or publication decision for their own article. Editorials and obituaries written by the journal’s editor do not undergo external peer review.

Peer-review procedures

All manuscripts submitted to Society of Diabetic Nephropathy Prevention journals are subject to rigorous review. This review consists of the following steps:

1. Initial submissions are reviewed by internal staff to ensure adherence to policies of Society of Diabetic Nephropathy Prevention, including ethical requirements for human and animal experimentation.

2. Submissions are then assigned to an Editor for evaluation.

3. The Academic Editor decides whether reviews from additional experts are needed to evaluate the manuscript. The majority of submissions are evaluated by two external reviewers, but it is up to the Editor to determine the number of reviews required.

4. After evaluation, the Editor chooses between the following decisions:

1. Accept

2. Minor Revision

3. Major Revision

4. Reject

5. If the decision is Minor Revision or Major Revision, authors have 30 days to resubmit the revised manuscript. Authors may contact email address if they require an extension.

6. Upon resubmission, the Editor may choose to send the manuscript back to external reviewers, or may render a decision based on personal expertise.

Permissions

It is the author’s responsibility to secure all permissions prior to publication.

Material from other sources

Any written or illustrative material that has been or will be published elsewhere must be duly acknowledged and accompanied by the written consent of the copyright holder (this may be the publisher rather than the author). This includes your own previously published material, if you are not the copyright holder.

Reproducing material published by Society of Diabetic Nephropathy Prevention

Materials published by Society of Diabetic Nephropathy Prevention may be reproduced in full or part in any medium or language only on the condition that the original material is cited properly.

Publication

The publication frequency and all related information regarding the journals are listed on their website.

Copyright and licensing

Open access agreement

Upon submitting an article, authors are asked to indicate their agreement to abide by an open access Creative Commons license (CC-BY). Under the terms of this license, authors retain ownership of the copyright of their articles. However, the license permits any user to download, print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work. The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.

Advertising

For advertising in a periodical published by Society of Diabetic Nephropathy Prevention, please consult the Publications Office at This email address is being protected from spambots. You need JavaScript enabled to view it. email address

 

Editorial Policies of Society of Diabetic Nephropathy Prevention

Editorial Policies Adopted by Scholarly Journals Published by Society of Diabetic Nephropathy Prevention

Authorship

The ICMJE recommends that authorship be based on the following 4 criteria:

1. Substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data.

2. Drafting the work or revising it critically for important intellectual content.

3. Final approval of the version published.

4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

In addition to being accountable for the parts of the work he or she has done, an author should be able to identify which co-authors are responsible for specific other parts of the work. In addition, authors should have confidence in the integrity of the contributions of their coauthors. All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be listed in an Acknowledgements section. Participation solely in the acquisition of funding, the gathering of data, technical help, writing assistance, and general supervision of the research group does not warrant authorship. Financial and material support should also be acknowledged. Please guarantee that anyone stated in the Acknowledgements section has granted its clearance for permission to be listed.

Contributorship statement

A contributorship statement is required for every manuscript submitted and should state who has contributed what to the planning, conduct, and reporting of the work described in the article.

Acknowledgements

Recognize individuals who provided assistance to the project. Report all sources of grant and other support for the project or study, including funds received from contributors, institutions and commercial sources. Consultancies and funds paid directly to investigators must also be listed.

Authorship Changes

Any change in authorship (i.e., order, addition, and deletion of authors) after initial submission must be approved by all authors. Authors should determine the order of authorship among themselves. In addition, any alterations must be clarified to the Editor/Editor-in-chief.

Competing interests

A competing interest exists when professional judgment concerning a primary interest (such as patients’ welfare or the validity of research) may be influenced by a secondary interest (such as financial gain - employment, consultancies, stock ownership or options, honoraria, patents, and paid expert- testimony or personal relationship). There is nothing unethical about a competing interest but it should be acknowledged and clearly stated. All authors must declare all competing interests in their covering letter and in “Competing Interests” section at the end of the manuscript file (before the references). Authors with no competing interests to declare should obviously state that.

The policy of Society of Diabetic Nephropathy Prevention is that none of the editors should have any financial relationship with any biomedical company.

Ethical approval of research/Publication Ethics

Society of Diabetic Nephropathy Prevention journals are following of the Committee on Publication Ethics (COPE) and aim to adhere to its Best Practice Guidelines.

We strongly consider allegations of publication misconduct, both before and after publication, and we reserve the right to contact authors' institutions, funders, or regulatory bodies if needed. If we find conclusive evidence of misconduct, we will take steps to correct the scientific record, which may include supplying a correction or retraction.

Authors are expected to be aware of publication ethics, specifically with regard to authorship, dual submission, plagiarism, figure manipulation, competing interests, and compliance with standards of research ethics. In cases of suspected misconduct, we will follow COPE standards and practices and may seek advice from the COPE forum if needed.

Statement of Ethics Approval

We require every research article submitted to include a statement that the study obtained ethics approval (or a statement that it was not required and why), including the name of the ethics committee(s) or institutional review board(s), the number/ID of the approval(s), and a statement that participants gave informed consent before taking part. Even when a study has been approved by a research ethics committee or institutional review board, editors may ask authors for more detailed information about the ethics of the work.

Patient consent and confidentiality

Any article that contains personal medical information about an identifiable living individual requires the patient’s explicit consent before we can publish it. We would like the patient to sign our consent form, which requires the patient to have read the article.

If consent cannot be obtained because the patient cannot be traced then publication will be possible only if the information can be sufficiently anonymized. Anonymization means that neither the patient nor anyone else could identify the patient with certainty.

If the patient is dead the authors should seek permission from a relative (as a matter of courtesy and medical ethics). If the relatives are not contactable we will balance the worthwhileness of the case, the likelihood of identification, and the likelihood of offence if identified in making a decision on whether we should publish without a relative’s consent.

Our policy on obtaining consent for publication of pictures of patients is a subset of our general policy on patient confidentiality. If there is any chance that a patient may be identified from a photograph or other image or from its legend or accompanying text we need the patient’s written consent to publication by Society of Diabetic Nephropathy Prevention.

Images – such as x-rays, laparoscopic images, ultrasound images, pathology slides, or images of undistinctive parts of the body – may be used without consent so long as they are anonymized by the removal of any identifying marks and are not accompanied by text that could reveal the patient’s identity through clinical or personal detail.

Research reporting guidelines

Authors are encouraged to use the relevant research reporting guidelines for the study type provided by the EQUATOR Network. This will ensure that you provide enough information for editors, peer reviewers and readers to understand how the research was performed and to judge whether the findings are likely to be reliable.

The key reporting guidelines are:

Randomized controlled trials (RCTs):CONSORT guidelines

Systematic reviews and meta-analyses: PRISMA guidelinesand MOOSE guidelines

Observational studies in epidemiology: STROBE guidelinesand MOOSE guidelines

Diagnostic accuracy studies: STARD guidelines

Quality improvement studies: SQUIRE guidelines

Clinical trial registration

Based on ICMJE recommendations, a clinical trial defines as “any research project that prospectively assigns people or a group of people to an intervention, with or without concurrent comparison or control groups, to study the cause-and-effect relationship between a health-related intervention and a health outcome”.

In agreement with the ICMJE , journals published by Society of Diabetic Nephropathy Prevention will not consider reports of clinical trials unless they were registered prospectively before recruitment of any participants.

Trial Registration

As a condition of consideration for publication, journals published by Society of Diabetic Nephropathy Prevention require registration of all trials in a public trials registry that is acceptable to the ICMJE (any registry that is a primary register of the WHO International Clinical Trials Registry Platform www.who.int/ictrp /network/primary/en/index.html or in ClinicalTrials.gov, which is a data provider to the WHO ICTRP).

Plagiarism detection

Journals published by Society of Diabetic Nephropathy Prevention use iThenticate software, which is a plagiarism detector service that verifies the originality of content submitted before publication. If plagiarism is identified, we will follow COPE guidelines.

Plagiarism includes, but is not limited to:

Directly copying text from other sources

Copying ideas, images, or data from other sources

Reusing text from your own previous publications

Using an idea from another source with slightly modified language

If plagiarism is detected during the peer review process, the manuscript may be rejected. If plagiarism is detected after publication, we reserve the right to issue a correction or retract the paper, as appropriate. We reserve the right to inform authors' institutions about plagiarism detected either before or after publication.

Peer review policy

Journals from Society of Diabetic Nephropathy Prevention review all manuscript submissions, internally or externally.

Original research articles authored by a member of a journal’s editorial team are independently peer reviewed; an editor will have no input or influence on the peer review process or publication decision for their own article. Editorials and obituaries written by the journal’s editor do not undergo external peer review.

 

Peer Review Procedures

All manuscripts submitted to Society of Diabetic Nephropathy Prevention journals are subject to rigorous review. This review consists of the following steps:

1. Initial submissions are reviewed by internal staff to ensure adherence to policies of Society of Diabetic Nephropathy Prevention, including ethical requirements for human and animal experimentation.

2. Submissions are then assigned to an Editor for evaluation.

3. The Academic Editor decides whether reviews from additional experts are needed to evaluate the manuscript. The majority of submissions are evaluated by two external reviewers, but it is up to the Editor to determine the number of reviews required.

4. After evaluation, the Editor chooses between the following decisions:

1. Accept

2. Minor Revision

3. Major Revision

4. Reject

5. If the decision is Minor Revision or Major Revision, authors have 30 days to resubmit the revised manuscript. Authors may contact email address if they require an extension.

6. Upon resubmission, the Editor may choose to send the manuscript back to external reviewers, or may render a decision based on personal expertise.

Permissions

It is the author’s responsibility to secure all permissions prior to publication.

Material from other sources

Any written or illustrative material that has been or will be published elsewhere must be duly acknowledged and accompanied by the written consent of the copyright holder (this may be the publisher rather than the author). This includes your own previously published material, if you are not the copyright holder.

Reproducing material published by Society of Diabetic Nephropathy Prevention

Materials published by Society of Diabetic Nephropathy Prevention may be reproduced in full or part in any medium or language only on the condition that the original material is cited properly.

Publication

The publication frequency and all related information regarding the journals are listed on their website.

Copyright and Licensing

Open Access Agreement

Upon submitting an article, authors are asked to indicate their agreement to abide by an open access Creative Commons license (CC-BY). Under the terms of this license, authors retain ownership of the copyright of their articles. However, the license permits any user to download, print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work. The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.

Advertising

For advertising in a periodical published by Society of Diabetic Nephropathy Prevention, please consult the Publications Office at This email address is being protected from spambots. You need JavaScript enabled to view it. email address.

Journal of Nephropharmacology
Journal of Nephropathology

 

 

Journals of society of diabetic nephropathy prevention follow the principles and issues of, the Committee on Publication Ethics (COPE).

 

 

Journals of Society of Diabetic Nephropathy Prevention , are licensed under a Creative Commons Attribution 4.0 License.

 

 

 

 

 

 

 

 

 

Site Traffic

Today11
This month64
Total66202

Monday, 06 April 2020 20:21



 

 

 

Healthy eating and diabetes

 

 

 

 

 



 

 

Current Date & Time

Monday, 06 April 2020